Neuphoria Net Receivables from 2010 to 2026

NEUP Stock   4.05  0.02  0.49%   
Neuphoria Therapeutics Net Receivables yearly trend continues to be relatively stable with very little volatility. Net Receivables is likely to grow to about 14.4 M this year. During the period from 2010 to 2026, Neuphoria Therapeutics Net Receivables destribution of quarterly values had range of 19.5 M from its regression line and mean deviation of  5,396,490. View All Fundamentals
 
Net Receivables  
First Reported
2001-06-30
Previous Quarter
11.9 M
Current Value
1.8 K
Quarterly Volatility
3.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Neuphoria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuphoria Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 15.4 K or Other Operating Expenses of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.41, Dividend Yield of 0.0 or PTB Ratio of 5.0E-4. Neuphoria financial statements analysis is a perfect complement when working with Neuphoria Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Neuphoria Stock
Check out the analysis of Neuphoria Therapeutics Correlation against competitors.
To learn how to invest in Neuphoria Stock, please use our How to Invest in Neuphoria Therapeutics guide.
Evaluating Neuphoria Therapeutics's Net Receivables across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neuphoria Therapeutics's fundamental strength.

Latest Neuphoria Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Neuphoria Therapeutics over the last few years. It is Neuphoria Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuphoria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Neuphoria Net Receivables Regression Statistics

Arithmetic Mean4,931,843
Geometric Mean1,157,048
Coefficient Of Variation129.90
Mean Deviation5,396,490
Median644,042
Standard Deviation6,406,267
Sample Variance41T
Range19.5M
R-Value0.29
Mean Square Error40T
R-Squared0.09
Significance0.26
Slope370,214
Total Sum of Squares656.6T

Neuphoria Net Receivables History

202614.4 M
202513.7 M
202411.9 M
2023126.9 K
2022283.6 K
20214.7 M
2020192.9 K

About Neuphoria Therapeutics Financial Statements

Neuphoria Therapeutics shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although Neuphoria Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Neuphoria Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Neuphoria Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables13.7 M14.4 M

Pair Trading with Neuphoria Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Neuphoria Stock

  0.62OSE OSE Pharma SAPairCorr

Moving against Neuphoria Stock

  0.84VERA Vera Therapeutics Sell-off TrendPairCorr
  0.72EQ EquilliumPairCorr
  0.72DRUG Bright Minds BiosciencesPairCorr
  0.65DSGN Design TherapeuticsPairCorr
  0.61DXB Dimerix Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Neuphoria Stock Analysis

When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.